Deng Y, et al. - In atrial fibrillation (AF) patients with cancer, researchers compared non–vitamin K antagonist oral anticoagulants (NOACs) to warfarin in terms of efficacy and safety, via this systematic review and meta-analysis. The PubMed and Embase databases were systematically searched for the relevant publications until February 16, 2019. They extracted risk ratios with 95% CIs, which were pooled using a random-effects model. Overall, five studies with 8908 NOACs and 12,440 warfarin users were analyzed. In AF patients, no significant links were found between cancer status and risks of stroke or systemic embolism, major bleeding, or death. Lower or similar rates of thromboembolic and bleeding events and an attenuated risk of venous thromboembolism were reported in relation to NOACs vs warfarin in patients with AF and cancer.